Aastrom Biosciences, Inc. (ASTM)
-NasdaqCM 0.55 
0.01(1.79%) May 24, 3:59PM EDT
| Prev Close: | 0.56 |
|---|
| Open: | 0.56 |
|---|
| Bid: | 0.48 x 3000 |
|---|
| Ask: | 0.59 x 1000 |
|---|
| 1y Target Est: | 1.38 |
|---|
| Beta: | 0.91 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 0.55 - 0.57 |
|---|
| 52wk Range: | 0.52 - 2.35 |
|---|
| Volume: | 164,707 |
|---|
| Avg Vol (3m): | 454,394 |
|---|
| Market Cap: | 25.12M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.71 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Final Trade: Your First Move for Tuesday, May 28at CNBC(Fri, May 24)
- AASTROM BIOSCIENCES INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StaEDGAR Online(Fri, May 24)
- AASTROM BIOSCIENCES INC FinancialsEDGAR Online Financials(Wed, May 15)
- AASTROM BIOSCIENCES INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StaEDGAR Online(Mon, May 13)
- Aastrom Biosciences Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- AASTROM BIOSCIENCES INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Wed, May 8)
- Aastrom Biosciences Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed, May 8)
- AASTROM BIOSCIENCES INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Wed, May 8)
- Q1 2013 Aastrom Biosciences Earnings Release - After Market CloseCCBN(Wed, May 8)
- Aastrom to Host First Quarter 2013 Investor Call on May 8, 2013GlobeNewswire(Fri, May 3)
- AASTROM BIOSCIENCES INC Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Fri, May 3)
- Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.: Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan DrugsWall Street Transcript(Wed, May 1)
- Stem Cells: Invest At Your Own Perilat Seeking Alpha(Wed, May 1)
- Aastrom files to sell $25M in common stocktheflyonthewall.com(Mon, Apr 29)
- Regenerative Medicine's Time Has Comeat Seeking Alpha(Sun, Apr 28)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 947.11 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.56 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.13 |
|---|
| Mean Recommendation*: | 2.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Aastrom Biosciences, Inc., a development stage company, engages in the development of patient-specific, cell products for use in the treatment of severe, chronic ischemic cardiovascular diseases.
View More